AB0575 IMPACT OF PATIENT-REPORTED DISEASE ACTIVITY ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS. DATA FROM THE ALMENARA LUPUS COHORT

Background Health-related quality of life (HRQoL) is impaired in systemic lupus erythematosus (SLE) patients, but its association with physicians reported disease activity is modest to none. Objectives To determine the impact of patients reported disease activity on their HRQoL. Methods We evaluated patient-reported disease activity on SLE patients from the Almenara Lupus Cohort. Disease activity was assessed using the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) patient-reported outcome (PRO) which ranges between 0 and 1200 (the higher the score is, the worse the activity is); HRQoL was ascertained using the LupusQoL which ranges between 0 and 100 (the higher the score is, the better the HRQoL). Generalized estimating equations were performed for each domain of the LupusQoL and the LFA-REAL PRO measured at the previous visit; multivariable models were adjusted for possible confounders (age at diagnosis, gender, educational level, disease duration, SLEDAI-2K, SDI, prednisone dose, antimalarials and immunosuppressive drug use and the same domain of LupusQoL) measured at the same visit as the LFA-REAL PRO. B was reported per 10 units increase of the LFA-REAL PRO. Results A total of 259 patients and 582 visits were included. Mean (SD) LFA-REAL PRO was 242.91 (178.92). The most affected LupusQoL domains at baseline were burden to others 57.5 (SD 31.5), intimate relationship 64.1 (SD 33.1) and body image 62.6 (SD 30.7). LFA-REAL PRO predicted a worse HRQoL in all domains, even after adjustment by possible confounders (Table 1). Conclusion A higher patient-reported disease activity predicted a worse HRQoL in SLE patients, even after adjustment for possible confounders. Strategies to improve how the patients feel and manage their disease could be useful to improve their HRQoL. Patient-reported disease activity should be included in the evaluation of SLE patients on a regular basis. Table 1. Impact of LFA-REAL PRO per 10-unit increase on HRQoL in SLE patients HRQoL domains Univariable Multivariable* B (SE) p value B (SE) p value Physical health -0.74 (0.06) <0.001 -0.40 (0.05) <0.001 Pain -0.89 (0.06) <0.001 -0.63 (0.06) <0.001 Planning -0.81 (0.06) <0.001 -0.47 (0.06) <0.001 Intimate relationship -0.58 (0.10) <0.001 -0.36 (0.08) <0.001 Burden to others -0.72 (0.08) <0.001 -0.40 (0.07) <0.001 Emotional health -0.70 (0.07) <0.001 -0.43 (0.06) <0.001 Body image -0.47 (0.09) <0.001 -0.35 (0.08) <0.001 Fatigue -0.77 (0.06) <0.001 -0.42 (0.06) <0.001 SE: Standard error. * Multivariable models were adjusted by age at diagnosis, gender, educational level, disease duration, SLEDAI-2K, SDI, prednisone dose, antimalarials and immunosuppressive drug use and the same domain of LupusQoL REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests Manuel F. Ugarte-Gil Speakers bureau: GSK, Consultant of: Aztra Zeneca, Grant/research support from: Janssen, Rocío Violeta Gamboa Cárdenas: None declared, Victor Pimentel-Quiroz: None declared, Cristina Reategui Sokolova: None declared, Claudia Elera-Fitzcarrald: None declared, Jose Alfaro Lozano: None declared, Cesar Pastor Asurza: None declared, Zoila Rodriguez Bellido: None declared, Risto Perich Campos: None declared, Graciela S Alarcon: None declared.